[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-events-search:[\"\",\"\",\"DDG\",\"1990-01-01\",\"2026-11-18\",1]":3,"fda-latest-sync-dates":26},{"events":4,"total":25},[5],{"mdr_report_key":6,"report_number":7,"event_type":8,"date_received":9,"date_of_event":10,"report_source_code":11,"adverse_event_flag":12,"product_problem_flag":13,"product_problems":14,"brand_name":16,"generic_name":17,"product_code":18,"manufacturer_name":19,"model_number":20,"patient_outcomes":21,"remedial_action":22,"created_at":23,"updated_at":24},"50088032","1823260-2026-03120","Malfunction","2026-07-30","2026-06-30","Manufacturer report","N","Y",[15],"Non Reproducible Results","Tina-quant Transferrin  ver.2  (urine  application)","TRANSFERRIN, ANTIGEN, ANTISERUM, CONTROL","DDG","Roche Diagnostics","",[20],[20],"2026-08-19T02:29:01.064007+00:00","2026-08-19T02:36:41.04148+00:00",1,{"510k":27,"classification":28,"enforcement":29,"event":30,"event_backfill":31,"pma":32,"warning_letter":33},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]